Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin

Completed

• Conditions: Bone and Joint Infection; Antibiotic Resistant Staphylococcus Aureus Infection
• Interventions: Other: Role of rifampin in staphylococcal PJI

• Registration Number: NCT03750721
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-04-01
• Primary Completion: 2018-05-01
• Study Completion: 2018-05-01
• Study First Submitted: 2018-08-07
• Status Verified: 2018-11
• Study First Submitted QC: 2018-11-20
• Last Update Submitted: 2018-11-20
• Study First Posted: 2018-11-23
• Last Update Posted: 2018-11-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

patients having had acute PJI (i.e. <1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)

Read More

Exclusion Criteria

None

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Role of rifampin in staphylococcal PJI	Role of rifampin in staphylococcal PJI	retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (\< 1 month) PJI treated with DAIR in 2011-2016 period

Primary Outcome Measures

Name	Time	Method
description of the use of rifampicin : rate of use	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)	the aim is to determine how the use of rifampin influence the prognosis in staphylococcal acute post-operative prosthetic joint infection treated with DAIR

Secondary Outcome Measures

Name	Time	Method
rate of failure for treatment using rifampin	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
rate of adverse event with rifampin	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)	Description of adverses events leading to stop the rifampicin

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon, France